These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

655 related articles for article (PubMed ID: 37055849)

  • 1. Novel strategies for cancer immunotherapy: counter-immunoediting therapy.
    Liu S; Sun Q; Ren X
    J Hematol Oncol; 2023 Apr; 16(1):38. PubMed ID: 37055849
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cancer immunoediting and resistance to T cell-based immunotherapy.
    O'Donnell JS; Teng MWL; Smyth MJ
    Nat Rev Clin Oncol; 2019 Mar; 16(3):151-167. PubMed ID: 30523282
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cancer Immunoediting in the Era of Immuno-oncology.
    Gubin MM; Vesely MD
    Clin Cancer Res; 2022 Sep; 28(18):3917-3928. PubMed ID: 35594163
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Immunoediting Dynamics in Glioblastoma: Implications for Immunotherapy Approaches.
    Amin T; Hossain A; Jerin N; Mahmud I; Rahman MA; Rafiqul Islam SM; Islam SMBU
    Cancer Control; 2024; 31():10732748241290067. PubMed ID: 39353594
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Therapeutic applications of the cancer immunoediting hypothesis.
    Desai R; Coxon AT; Dunn GP
    Semin Cancer Biol; 2022 Jan; 78():63-77. PubMed ID: 33711414
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Recent Advances of RNA m
    Ma S; Barr T; Yu J
    Cancer Treat Res; 2023; 190():49-94. PubMed ID: 38112999
    [TBL] [Abstract][Full Text] [Related]  

  • 7. From Cancer Immunoediting to New Strategies in Cancer Immunotherapy: The Roles of Immune Cells and Mechanics in Oncology.
    Aragon-Sanabria V; Kim GB; Dong C
    Adv Exp Med Biol; 2018; 1092():113-138. PubMed ID: 30368751
    [TBL] [Abstract][Full Text] [Related]  

  • 8. New insights into cancer immunoediting and its three component phases--elimination, equilibrium and escape.
    Mittal D; Gubin MM; Schreiber RD; Smyth MJ
    Curr Opin Immunol; 2014 Apr; 27():16-25. PubMed ID: 24531241
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Quantification of Neoantigen-Mediated Immunoediting in Cancer Evolution.
    Wu T; Wang G; Wang X; Wang S; Zhao X; Wu C; Ning W; Tao Z; Chen F; Liu XS
    Cancer Res; 2022 Jun; 82(12):2226-2238. PubMed ID: 35486454
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Tumor-Derived Extracellular Vesicles in Cancer Immunoediting and Their Potential as Oncoimmunotherapeutics.
    Najaflou M; Shahgolzari M; Khosroushahi AY; Fiering S
    Cancers (Basel); 2022 Dec; 15(1):. PubMed ID: 36612080
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Cancer Immunoediting in the Development of Cancer Immunotherapy].
    Ariyasu R; Nishikawa H
    Gan To Kagaku Ryoho; 2019 Mar; 46(3):407-411. PubMed ID: 30914573
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Immune Therapy Resistance and Immune Escape of Tumors.
    Seliger B; Massa C
    Cancers (Basel); 2021 Feb; 13(3):. PubMed ID: 33535559
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The senescence journey in cancer immunoediting.
    Zingoni A; Antonangeli F; Sozzani S; Santoni A; Cippitelli M; Soriani A
    Mol Cancer; 2024 Apr; 23(1):68. PubMed ID: 38561826
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Exosomes in cancer immunoediting and immunotherapy.
    Zhao Y; Liu L; Sun R; Cui G; Guo S; Han S; Li Z; Bai T; Teng L
    Asian J Pharm Sci; 2022 Mar; 17(2):193-205. PubMed ID: 35582642
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Immunogenomic pan-cancer landscape reveals immune escape mechanisms and immunoediting histories.
    Mizuno S; Yamaguchi R; Hasegawa T; Hayashi S; Fujita M; Zhang F; Koh Y; Lee SY; Yoon SS; Shimizu E; Komura M; Fujimoto A; Nagai M; Kato M; Liang H; Miyano S; Zhang Z; Nakagawa H; Imoto S
    Sci Rep; 2021 Aug; 11(1):15713. PubMed ID: 34344966
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Developing an effective breast cancer vaccine: challenges to achieving sterile immunity versus resetting equilibrium.
    Curigliano G; Criscitiello C; Esposito A; Fumagalli L; Gelao L; Locatelli M; Minchella I; Goldhirsch A
    Breast; 2013 Aug; 22 Suppl 2():S96-9. PubMed ID: 24074802
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Reprogramming the tumor microenvironment to improve the efficacy of cancer immunotherapies.
    Faraj JA; Al-Athari AJH; Mohie SED; Kadhim IK; Jawad NM; Abbas WJ; Jalil AT
    Med Oncol; 2022 Sep; 39(12):239. PubMed ID: 36175691
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Suppressive Myeloid Cells Shape the Tumor Immune Microenvironment.
    Xiong J; Wang H; Wang Q
    Adv Biol (Weinh); 2021 Mar; 5(3):e1900311. PubMed ID: 33729699
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cancer Immunoediting: Elimination, Equilibrium, and Immune Escape in Solid Tumors.
    Wilczyński JR; Nowak M
    Exp Suppl; 2022; 113():1-57. PubMed ID: 35165859
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cancer immunoediting: antigens, mechanisms, and implications to cancer immunotherapy.
    Vesely MD; Schreiber RD
    Ann N Y Acad Sci; 2013 May; 1284(1):1-5. PubMed ID: 23651186
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 33.